

Christina Lake Cannabis Corp.
Condensed Interim Financial Statements
For the nine months ended August 31, 2021 and 2020
(Unaudited - Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW

Under National Instrument 51-102, Part 4 subsection 4.3 (3), if an auditor has not performed a review of the unaudited condensed interim financial statements, they must be accompanied by a notice indicating that the unaudited condensed interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of Christina Lake Cannabis Corp. have been prepared by and are the responsibility of management.

These unaudited condensed interim financial statements for the nine months ended August 31, 2021 have not been reviewed or audited by the Company's independent auditors in accordance with standards established by the Chartered Professional Accountants of Canada.

Christina Lake Cannabis Corp.
Condensed Interim Statements of Financial Position
(Expressed in Canadian Dollars - Unaudited)

As at,	Notes	August 31, 2021	November 30, 2020 (Audited)
ASSETS			
Current assets			
Cash		\$ 1,427,006	\$ 1,844,356
Receivables		670,531	71,808
Prepaid expenses		161,541	129,964
Inventory	6	6,298,361	6,222,808
Biological asset	5	6,422,577	-
		14,980,016	8,268,936
Non-current assets			
Property, plant and equipment	4	9,828,180	9,534,850
TOTAL ASSETS		\$ 24,808,196	\$ 17,803,786
LIABILITIES			
Current liabilities			
Accounts payable and accrued liabilities	7	\$ 588,108	\$ 670,929
Current portion of loan	10	3,910	3,910
Current portion of lease liability	11	12,256	29,562
Current portion of preferred shares	13	1,110,784	1,110,784
Current Portion of convertible debentures	9	3,708,157	-
		5,423,215	1,815,185
Non-current liabilities			
Government loan	8	29,564	26,737
Convertible debentures	9	-	3,982,218
Non-current portion of loan	10	7,494	10,427
Non-current portion of lease liability	11	-	4,652
Non-current portion of preferred shares	13	3,019,834	2,509,314
TOTAL LIABILITIES		8,480,107	8,348,533
SHAREHOLDERS' EQUITY			
Share capital	13	19,380,991	11,735,608
Equity component of convertible debenture	9	418,080	557,111
Obligation to issue shares	13	279,500	679,500
Reserves	13	2,409,837	2,293,149
Deficit		(6,160,319)	(5,810,115)
TOTAL SHAREHOLDERS' EQUITY		16,328,089	9,455,253
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		\$ 24,808,196	\$ 17,803,786

Nature and continuance of operations (Note 1)

Subsequent events (Note 16)

Approved on behalf of the Board:

“Joel Dumaresq”

Joel Dumaresq, Director

“Gil Playford”

Gil Playford, Director

Christina Lake Cannabis Corp.
Condensed Interim Statements of Loss and Comprehensive Loss
(Expressed in Canadian Dollars - Unaudited)

Three and nine months period ended,	Notes	Three months ended		Nine months ended	
		August 31, 2021	August 31, 2020	August 31, 2021	August 31, 2020
		\$	\$	\$	\$
Revenue					
Revenue from sale of goods		1,290,722	-	1,569,881	-
Cost of sales		(532,428)	-	(623,933)	-
Gross profit before fair value adjustments		758,294	-	945,948	-
Changes in fair value of inventory sold		(742,593)	-	(918,074)	-
Gross profit from sale of goods		15,701	-	27,874	-
Fair value change on growth of biological asset		5,430,173	3,046,237	5,430,173	3,046,237
General and administrative expenses					
Accretion	8,9,11	188,880	79,129	382,214	134,989
Consulting fees	12	122,133	343,973	328,733	450,367
Communication expense		1,975	-	69,021	-
Corporate development		-	-	365,872	-
Depreciation	4	77,080	7,166	381,028	14,331
Foreign exchange		(4)	-	(451)	-
Interest expense	9	182,066	109,189	452,711	176,902
Insurance		21,478	10,088	62,370	30,422
Management fees	12	36,000	-	108,000	-
Marketing		1,574	-	403,884	-
Nursery expenses		30,156	(73,385)	36,864	65,466
Office and miscellaneous		49,589	50,227	229,784	236,653
Professional fees		240,963	106,941	398,095	222,266
Property taxes		-	-	30,566	25,144
Salaries	12	318,237	145,431	1,037,998	652,711
Share based compensation	12,13	372,531	1,272,522	924,935	1,429,777
Repairs and maintenance		17,475	-	35,579	-
Regulatory fees		5,898	117,193	84,155	155,205
Total general and administrative expenses		(1,666,031)	(2,168,474)	(5,331,358)	(3,594,233)
Other items					
Accounts payable write down		-	-	(38,528)	32,817
Fair value preferred shares	13	-	-	510,521	-
Loss on sale of equipment		-	-	4,900	-
Total other items		-	-	(476,893)	-
Net and comprehensive income (loss) for the period					
		\$ 3,779,843	\$ 877,763	\$ (350,204)	\$ (515,179)
Loss per share – basic and diluted					
		\$ 0.03	\$ 0.01	\$ (0.00)	\$ (0.01)
Weighted average number of common shares outstanding					
		112,607,372	81,004,447	105,639,215	78,071,770

The accompanying notes are an integral part of these condensed interim financial statements

Christina Lake Cannabis Corp.
Condensed Interim Statement of Changes in Shareholders' Equity
(Expressed in Canadian Dollars - Unaudited)

	Share capital		Common shares		Obligation to issue shares	Equity component of convertible liability	Reserves	Deficit	Total
	Number of shares #	Amount \$	Number of shares #	Amount \$					
Balance at November 30, 2019	76,119,202	8,093,927	-	-	104,932	-	539,940	(2,957,476)	5,781,323
Loss for the period	-	-	-	-	-	-	-	(515,179)	(515,179)
Shares for consulting services	604,110	120,822	-	-	300,068	-	(15,890)	-	405,000
Options exercised	1,806,600	340,557	-	-	-	-	(177,963)	-	162,594
Private placement	5,484,103	1,630,415	-	-	-	-	-	-	1,630,415
Class B preferred shares	-	-	2,000,000	1,700,000	300,000	-	-	-	2,000,000
Fair value of finder's fee warrants issued	-	-	-	-	-	-	60,103	-	60,103
Equity component of convertible liability	-	-	-	-	-	568,448	-	-	568,448
Share based compensation	-	-	-	-	-	-	1,024,777	-	1,024,777
Balance at August 31, 2020	84,014,015	10,185,721	2,000,000	1,700,000	705,000	568,448	1,430,967	(3,472,655)	11,117,481
Balance at November 30, 2020	90,440,315	11,735,608	-	-	679,500	557,111	2,293,149	(5,810,115)	9,455,253
Loss for the period	-	-	-	-	-	-	-	(350,204)	(350,204)
Private placement, net of share issuance costs	12,054,359	4,216,794	-	-	(530,000)	-	50,389	-	3,737,183
Warrants exercised	4,476,000	1,230,303	-	-	-	-	(60,103)	-	1,170,200
Options exercised	1,839,500	637,238	-	-	-	-	(350,433)	-	286,805
Conversion of convertible debenture	5,936,000	1,242,948	-	-	-	(139,031)	-	-	1,103,917
Shares issued in lieu of cash	300,000	60,000	-	-	(60,000)	-	-	-	-
Shares issued to consultants	445,000	258,100	-	-	-	-	-	-	258,100
Obligation to issue shares	-	-	-	-	190,000	-	-	-	190,000
Share based compensation	-	-	-	-	-	-	476,835	-	476,835
Balance at August 31, 2021	115,491,174	19,380,991	-	-	279,500	418,080	2,409,837	(6,160,319)	16,328,089

The accompanying notes are an integral part of these condensed interim financial statements

Christina Lake Cannabis Corp.
Condensed Interim Statements of Cash Flows
(Expressed in Canadian Dollars - Unaudited)

Nine months period ended,	August 31, 2021 \$	August 31, 2020 \$
Operating activities		
Loss for the period	(350,204)	(515,179)
Non-cash items:		
Accretion	382,214	134,979
Accounts payable write down	(38,528)	(32,817)
Change in estimate of preferred shares	510,520	-
Depreciation	381,028	14,331
Fair value change of biological asset	(5,430,173)	-
Foreign exchange	-	(2,451)
Interest expense	451,911	176,902
Loss on sale of equipment	4,900	-
Share-based compensation	924,935	1,024,777
Shares for consulting fees	-	405,000
Fair value transfer of inventory	918,074	(3,046,237)
Changes in non-cash working capital items:		
Decrease in receivables	(598,723)	61,802
Increase in prepaid	(31,577)	(4,061)
Increase in Inventory	(769,290)	-
Biological asset	(771,207)	(561,573)
Increase in accounts payable and accrued liabilities	(49,826)	(24,781)
Net cash flows used in operating activities	(4,465,946)	(2,369,308)
Investing activities		
Net equipment purchases	(945,122)	(2,222,016)
Building improvements	(204,170)	(1,833,857)
Proceeds from sale of equipment	24,500	-
Lease liability	-	14,835
Net cash flows used in investing activities	(1,124,792)	(4,041,038)
Financing activities		
Proceeds from private placement	3,737,183	1,630,415
Proceeds from preferent shares issued	-	2,000,000
Subscription receivable	-	95,005
CERB Loan received from Government	-	40,000
Proceeds on convertible debentures, net of issuance costs	-	4,104,261
Lease liability	(20,800)	-
Options exercised	286,805	-
Warrants exercised	1,170,200	162,594
Net cash flows from financing activities	5,173,388	8,032,275
Increase (decrease) in cash	(417,350)	1,621,929
Cash, beginning of year	1,844,356	740,973
Cash, end of period	1,427,006	2,362,902
Supplemental non-cash flow information:		
Periods ended,	August 31, 2021 \$	August 31, 2020 \$
Equity portion of on conversion of convertible debentures	139,031	-
Fair value of finder warrants	-	35,112
Obligation to issue shares	-	300,000
Reclass fair value portion on obligation to issue shares	-	15,890
Shares issued upon conversion of convertible debentures	1,242,948	-

The accompanying notes are an integral part of these condensed interim financial statements

1. Nature and continuance of operations

Christina Lake Cannabis Corp. (the “Company”) was incorporated on October 26, 2014, under the laws of the province of British Columbia, Canada. On December 21, 2018, the Company changed its name from Cervantes Capital Corp. to Christina Lake Cannabis Corp. The Company is a licensed producer of cannabis in British Columbia under the Cannabis Act with a standard cultivation, processing and sales license and a research and development license. On October 1, 2020, the Company began trading on the Canadian Securities Exchange under the ticker symbol “CLC” and on the OTC Markets Group Inc. under the ticker symbol “CLCFF.”

The Company’s principal address, records office and registered address are located at Suite 810 – 789 West Pender Street, Vancouver, BC, V6C 1H2.

These condensed interim financial statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations. The Company is in the development stage and currently has no sources of cash from operations. As at August 31, 2021, the Company had accumulated losses of \$6,160,319 (2020 - \$5,810,115). The Company’s continuation as a going concern is dependent upon the Company to successfully harvest its cannabis and earn revenues from the sale of cannabis to meet current and future obligations and ultimately achieve profitable operations. These factors indicate the existence of a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. Management intends to successfully harvest and sell cannabis to achieve profitability from its business activities.

In March 2020 the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. While the extent of the impact is unknown, the Company anticipates this outbreak might increase the difficulty in capital raising which may negatively impact the Company’s business operation and financing condition.

2. Basis of preparation

These unaudited condensed interim financial statements were approved and authorized for issue on October 29, 2021 by the directors of the Company.

These condensed interim financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

Statement of compliance

These condensed interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” (“IAS 34”) using accounting policies consistent with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”) and Interpretations of the IFRS Interpretations Committee.

These unaudited condensed interim financial statements do not include all of the information required of a full annual financial report and is intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that this financial report be read in conjunction with the audited financial statements of the Company for the year ended November 30, 2020.

2. Basis of preparation (Continued)

Basis of presentation

These condensed interim financial statements have been prepared on an historical cost basis, except for financial instruments which are classified as fair value through profit or loss. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information. All amounts on the condensed interim financial statements are presented in Canadian dollars which is the functional currency of the Company.

Significant estimates and assumptions

The preparation of the Company's condensed interim financial statements in conformity with IFRS requires management to make estimates and assumptions concerning the future. Estimates and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from these estimates.

Areas requiring a significant degree of estimation relate to the fair value measurements for financial instruments and biological assets, discount rate on lease liability, convertible debentures and preferred shares, assumptions used in the cash flow projection for preferred shares, useful lives and valuation of property, plant and equipment and the recoverability and measurement of deferred tax assets and liabilities. Actual results may differ from those estimates.

3. Significant accounting policies

The condensed interim financial statements are presented in Canadian dollars and are prepared in accordance with the same accounting policies, critical estimates and methods described in the Company's annual financial statements, except for the adoption of new accounting standards and/or estimates identified in Note 3. Given that certain information and disclosures, which are included in the annual audited consolidated financial statements, have been condensed or excluded in accordance with IAS 34, these financial statements should be read in conjunction with our annual audited consolidated financial statements as at and for the year ended November 30, 2020, including the accompanying notes thereto.

Revenues

Revenue is measured at the fair value of the consideration received or receivable, net of estimated returns and discounts. The Company considers the terms of the sales contracts as well as industry practices, taking into consideration the type of customer, the nature of the transaction and the specific circumstances of each arrangement.

The Company's revenue is comprised of sales of cannabis products including cannabis biomass, distillate and other derivatives. Revenue from the sale of goods is recognized when control of the goods has been transferred to the customer under the terms of an enforceable contract. The Company satisfies its performance obligation and transfers control to the customer upon shipment. Anticipated product returns are provided for at the time of sale. Billings rendered in advance of performance under contracts are recorded as deferred revenue.

Recent Accounting Pronouncements

As at the date of authorization of these financial statements, the IASB and the IFRS Interpretations Committee had issued certain pronouncements that are mandatory for the Company's accounting periods commencing on or after January 1, 2021. Many are not applicable or do not have a significant impact to the Company, have been excluded. The Company had assessed that no material impact is expected upon the adoption of the following amendments on its consolidated financial statements:

3. Significant accounting policies (Continued)

Recent Accounting Pronouncements

Amendments to IAS 1

In January 2020, the IASB issued amendments to IAS 1 which clarify the requirements for classifying liabilities as either current or non-current by: (i) specifying that the conditions which exist at the end of the reporting period determine if a right to defer settlement of a liability exists; (ii) clarifying that settlement of a liability refers to the transfer to the counterparty of cash, equity instruments, other assets or services; (iii) clarifying that classification is unaffected by management's expectation about events after the balance sheet date; and (iv) clarifying the classification requirements for debt an entity may settle by converting it into equity.

The amendments clarify existing requirements, rather than make changes to the requirements, and so are not expected to have a significant impact on an entity's financial statements. However, the clarifications may result in reclassification of some liabilities from current to non-current or vice-versa, which could impact an entity's loan covenants. Because of this impact, the IASB has provided a longer effective date to allow entities to prepare for these amendments. In July 2020, the IASB issued an amendment to defer the effective date of the amendments by one year from its originally planned effective date to annual periods beginning on or after January 1, 2023 due to the impact of COVID-19. Early application is permitted.

Amendments to IAS 37 – Provisions, Contingent Liabilities and Contingent Assets (“IAS 37”)

In May 2020, the IASB issued amendments to update IAS 37. The amendments specify that in assessing whether a contract is onerous under IAS 37, the cost of fulfilling a contract includes both the incremental costs and an allocation of costs that relate directly to contract activities. The amendments also include examples of costs that do, and do not, relate directly to a contract. These amendments are effective for annual periods beginning on or after January 1, 2022. Earlier application is permitted.

4. Property, plant and equipment

On March 27, 2020, the Company was granted the Standard Cultivation License (“SCL”) from Health Canada for the Company's 32-acre phase 1 facility. This license authorizes the cultivation and sale of cannabis under the Cannabis Act and provides the Company with over 950,000 sf of licensed outdoor cultivation space.

	Right-of-use asset	Equipment	Land	Building	Building improvement	Total
	\$	\$	\$	\$	\$	\$
November 30, 2019	-	225,394	1,088,397	394,875	3,471,668	5,180,334
Additions	59,924	2,704,363	-	-	1,814,350	4,578,637
Depreciation	(21,496)	(133,317)	-	-	(69,308)	(224,121)
November 30, 2020	38,428	2,796,440	1,088,397	394,875	5,216,710	9,534,850
Additions	-	953,893	-	-	204,170	1,158,063
Deduction	-	(44,113)	-	-	-	(44,113)
Depreciation	(21,713)	(581,096)	-	-	(217,811)	(820,620)
August 31, 2021	16,715	3,125,124	1,088,397	394,875	5,203,069	9,828,180

The right-of-use asset relates to leased equipment for the production and cultivation of cannabis. The lease is reflected on the balance sheet as a right-of-use asset, with an associated lease liability (Note 11). The discount rate applied to the lease is 8%.

During the period ended August 31, 2021, the Company capitalized depreciation of \$221,197 (2020 - \$Nil) as a biological asset cost and \$224,337 (2020 - \$Nil) as inventory processing costs.

5. Biological asset

Biological assets are comprised of:

	Amount \$
Balance at November 30, 2018 and 2019	-
Changes in fair value less cost to sell due to biological transformation	4,767,202
Production cost capitalized	1,315,032
Transferred to inventory upon harvest	(6,082,234)
Balance at November 30, 2020	-
Changes in fair value less cost to sell due to biological transformation	5,430,173
Production cost capitalized	992,404
Transferred to inventory upon harvest	-
Balance at August 31, 2021	6,422,577

Measurement of the biological transformation of the plant at fair value less costs to sell begins in the fourth week prior to harvest and is recognized evenly until the point of harvest. The Company has determined the fair value less costs to sell of cannabis biomass to be \$4 per gram and harvested yield of biomass is between 1,100 to 1,400 grams per plant. As at August 31, 2021, the Company's crop is such that a biological asset fair value has been applied.

The fair value of biological assets is determined using a valuation model to estimate expected harvest yield per plant applied to the estimated price per gram less processing and selling costs. Only when there is a material change from the expected fair value used for cannabis does the Company make any adjustments to the fair value used.

Sales price used in the valuation of biological assets is based on the average selling price of all cannabis products and can vary based on different strains being grown as well as the proportion of sales derived from wholesale sales. Selling costs vary depending on methods of selling and are considered based on the expected method of selling and the determined additional costs which would be incurred. Expected yields for the cannabis plant is also subject to a variety of factors, such as strains being grown, length of growing cycle, and space allocated for growing. Management reviews all significant inputs based on historical information obtained.

These inputs are level 2 on the fair value hierarchy and are subject to volatility in market prices and several uncontrollable factors, which could significantly affect the fair value of biological assets in future periods.

6. Inventory

Inventory is comprised of cannabis biomass:

	Amount \$
Balance at November 30, 2019	-
Capitalized cost	140,574
Harvested cannabis biomass	6,082,234
Balance at November 30, 2020	6,222,808
Production cost capitalized	1,617,560
Cost of goods sold – fair value	(918,074)
Cost of goods sold	(623,933)
Balance at August 31, 2021	6,298,361

6. Inventory (Continued)

During the nine-month period ended August 31, 2021, the Company recorded \$1,393,223 of processing costs and depreciation of \$224,337.

As at August 31, 2021, the Company held the following inventory:

	August 31, 2021	November 30, 2020
	Kg	Kg
Dried cannabis biomass	6,781	31,210
Distillate	973	
Crude oil	888	-
Kief	135	-
Hemp	364	

7. Accounts payable and accrued liabilities

	August 31, 2021	November 30, 2020
Accounts payable	\$ 416,832	\$ 233,648
Accrued liabilities	171,276	437,281
	\$ 588,108	\$ 670,929

During the year ended November 30, 2020 the Company applied the \$30,000 deposits, which was received in 2019 fiscal year, toward a convertible debenture financing, which was completed during the year ended November 30, 2020 (Note 8).

8. CEBA Loan

The Company entered into a Canada Emergency Business Account “CEBA” loan with the Government of Canada.

The loan is an interest free loan of \$40,000 from the Government of Canada. If the Government of Canada is repaid by December 31, 2022, 25% being \$10,000 will be forgiven. If the Company is not able to repay, the loan will convert into a regular loan with a three-year term at 5% per annum. Upon initial recognition, the Company recorded a gain on government loan of \$15,309. During the nine-month period ended August 31, 2021, the Company recorded accretion expense of \$2,827 (2020 - \$Nil).

9. Convertible debentures

During the year ended November 30, 2020, the Company closed six tranches of unsecured convertible debenture financings (“Debentures”) with an aggregate face value of \$5,000 each. The Debentures bear interest of 12%, maturing in 24 months and the principal and interest are convertible into common shares at a conversion price of \$0.20, at the option of the debenture holders.

On March 13, 2020 the Company closed an unsecured convertible debentures financing for gross proceeds of \$1,800,000. The Company paid a finder’s fee of \$86,700 and issued 433,500 finder’s warrants (“Finder’s Warrants”) with a fair value of \$33,304. Each Finder’s Warrant entitles the holder to purchase one common share in the capital of the Company at a price of \$0.20 for a period of 12 months. The fair value of the warrants was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price of \$0.20; exercise price of \$0.20; a risk-free rate of 0.39%; and an expected life of the warrant of 1 year, and estimated expected volatility of 100% with no dividend yield.

9. Convertible debentures (continued)

On March 23, 2020 the Company closed an unsecured convertible debentures financing for gross proceeds of \$815,000. The Company paid a finder's fee of \$45,900 and issued 225,000 Finder's Warrants with a fair value of \$17,282. Each Finder's Warrant entitles the holder to purchase one common share in the capital of the Company at a price of \$0.20 for a period of 12 months. The fair value of the warrants was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price of \$0.20; exercise price of \$0.20; a risk-free rate of 0.36%; an expected life of the warrants of 1 year, and estimated expected volatility of 100% with no dividend yield.

On April 7, 2020, the Company closed an unsecured convertible debentures financing for gross proceeds of \$100,000. The Company paid a finder's fee of \$6,000 and issued 30,000 Finder's Warrants with a fair value of \$2,298. Each Finder's Warrant entitles the holder to purchase one common share in the capital of the Company at a price of \$0.20 for a period of 12 months from closing. The fair value of the warrants was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price of \$0.20; exercise price of \$0.20; a risk-free rate of 0.0%; an expected life of the warrants of 1 year, and estimated expected volatility of 100% with no dividend yield.

On May 14, 2020, the Company closed an unsecured convertible debenture financing for gross proceeds of \$35,000.

On May 25, 2020, the Company closed an unsecured convertible debentures financing for gross proceeds of \$255,000. The Company paid a finder's fee of \$15,000 and issued 75,000 Finder's Warrants with a fair value of \$5,758. Each finder's warrant entitles the holder to purchase one common share in the capital of the Company at a price of \$0.20 for a period of 12 months from closing. The fair value of the warrants was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price of \$0.20; exercise price of \$0.20; a risk-free rate of 0.3%, an expected life of the warrants of 1 year, and estimated expected volatility of 100% with no dividend yield.

On August 20, 2020, the Company closed an unsecured convertible debentures financing for gross proceeds of \$1,289,500. The Company paid a finder's fee of \$69,605 and issued 7,500 Finder's Warrants with a fair value of \$1,461. Each finder's warrant entitles the holder to purchase one common share in the capital of the Company at a price of \$0.20 for a period of 12 months from closing. The fair value of the warrants was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price of \$0.30; exercise price of \$0.20; a risk-free rate of 0.22%; an expected life of the warrants of 1 year, and estimated expected volatility of 100% with no dividend yield.

During the nine months ended August 31, 2021, Convertible debentures were converted to shares and 5,936,000 shares were issued, extinguishing \$1,103,917 in principal debt, and related interest.

9. Convertible debentures (continued)

The following table reconciles the recorded value of the liability and the equity components of the convertible debentures:

	Convertible debenture \$	Equity component of convertible debenture \$	Total \$
Balance, November 30, 2019	-	-	-
Additions	3,698,041	595,459	4,294,500
Debt issuance cost	(243,960)	(39,348)	(283,308)
Interest expense	296,413	-	296,413
Accretion expense	231,724	-	231,724
Balance, November 30, 2020	3,982,218	557,111	4,539,329
Conversion	(1,103,917)	(139,031)	(1,242,948)
Interest expense	451,911	-	451,911
Accretion expense	377,945	-	377,945
Balance, August 31, 2021	3,708,157	418,080	4,126,237

Management estimated that the fair value of the debentures using a discount rate of 20% with the residual value allocated to the equity component of the convertible debentures.

10. Loan payable

During the year ended November 30, 2020, the Company entered into a loan agreement to purchase equipment for \$15,640. The loan does not bear interest and matures in four years.

	\$
Balance, November 30, 2019	-
Loan additions	15,640
Repayments	(1,303)
Balance, November 30, 2020	14,337
Repayments	(2,933)
Balance, August 31, 2021	11,404
Current portion	3,910
Non-current portion	7,494

11. Lease liability

During the year ended November 30, 2020, the Company entered into lease agreements to lease a loader and generator for a period of 2 years. The Company recognized right-of-use asset of \$59,924 and lease liability of \$59,924. The Company recorded a right-of-use asset for leased equipment in the statement financial position as at November 30, 2020.

At the commencement date of the lease, the lease liability was measured as the present value of the future lease payments that were not paid at that date. These lease payments are discounted using a discount rate of 8%, which is the Company's estimated incremental borrowing rate.

11. Lease liability (continued)

The following is a continuity schedule of lease liabilities for the three-month period ended February 28, 2021:

	\$
Balance, November 30, 2019	-
Lease additions (Note 4)	59,924
Lease payments	(26,000)
Lease payment transferred to accounts payable	(2,600)
Accretion on lease liability	2,890
Balance, November 30, 2020	34,214
Lease payments	(23,400)
Accretion on lease liability	1,442
Balance, August 31, 2021	12,256
Current portion	12,256
Non-current portion	-

12. Related party transactions and balances

The Company has identified its directors and certain senior officers as its key management personnel.

During the period, the Company entered into transactions with related parties comprised of directors, officers and companies with common directors. The key management compensation and director fees consist of the following for the nine-month period ended August 31, 2021 and August 31, 2020:

	August 31, 2021	August 31, 2020
	\$	\$
Accounting fees paid to a private company controlled by the former CEO	-	53,192
Accounting fees included in Professional fees paid to the CFO	61,899	-
Consulting fees paid to a previous director of the Company	-	6,250
Consulting fees paid to a private company jointly controlled by the CEO	87,359	77,289
Consulting fees paid to an officer of the Company	82,500	-
Lease payments to a company controlled by a director	23,400	-
Management fees paid to CEO	108,000	-
Salaries paid to related parties	204,896	188,192
Share based payments	444,176	126,496
Shares issued in lieu of cash for consulting fees (Note 13)	-	225,822
	1,012,230	677,241

As at August 31, 2021, there was \$133,919 (November 30, 2020 - \$396,720) included in accounts payable and accrued liabilities for related parties of the Company. The balance is unsecured, due on demand and are non-interest bearing.

During the nine-month period ended August 31, 2021, the Company paid rent of \$Nil to a private company jointly controlled by the CEO (2020 - \$4,500).

During the nine-month period ended August 31, 2021, the Company paid lease payments of \$23,400 to a private company controlled by a director (2020- \$Nil).

12. Related party transactions and balances (continued)

During the nine-month period ending August 31, 2021, the Company has an obligation to issue 500,000 shares (November 30, 2020 - 250,000 shares) to the CEO in lieu of cash for consulting fees in the amount of \$279,500 (November 30, 2020 - \$89,500) (Note 13).

13. Share Capital

Authorized share capital

Unlimited number of common shares without par value.

Unlimited number of Class B preferred shares.

Issued share capital

At August 31, 2021, there were 115,491,174 (November 30, 2020 – 90,440,315) issued and fully paid common shares outstanding.

At August 31, 2021, there were 2,000,000 (November 30, 2020 – 2,000,000) issued and fully paid Class B preferred shares outstanding.

Preferred shares

During the year ended November 30, 2020, the Company closed a preferred share private placement for total proceeds of \$2,000,000 (“Preferred Share Capital”). The Company paid finder’s fees in cash of \$15,302 and issued 1,000,000 finder’s shares to Leede Jones Grable Inc., providing strategic advisory services to the Company related to the preferred share private placements.

The following terms apply to the Preferred Shares:

Cumulative dividends on the Preferred Shares shall accrue and become payable in arrears on a monthly basis, for a period of 48 months, based on the following calculation:

- Repayment of Preferred Share Capital: 40% of the total revenue received by the Company from the sale of cannabis oil, hemp oil and other such hemp and cannabis derivative extracts produced by the Company, less the cost of any third-party feedstock (the “Product Revenue”), up to cumulative aggregate Product Revenue of \$5,000,000; It shall be payable as a capital repayment of the Preferred shares; and
- Preferred Share Dividend: for cumulative aggregate Product Revenue exceeding \$5,000,000, immediately following the repayment of Preferred Share Capital, the Company shall accrue on a monthly basis an amount equal to the sum of: (A) \$80 per kilogram of dry cannabis produced and processed by the Company from its own feedstock; and (B) an amount equal to 35% of Product Revenue derived from third party feedstock.

The payment of all accrued and accumulated dividends shall be postponed for that portion of Product Revenue attributable to uncollected revenue (the “Revenue Receivable”) and the balance of the postponed accrued and accumulated dividend shall become payable in the month where the Revenue Receivable is received by the Company. No dividend shall accrue or be payable after 4 years from the date of issuance. The preferred shares are secured by certain production equipment.

The preferred shares have been classified as liability at amortized cost due to the requirement for the Company to deliver cash during the term of the agreement. At inception, the Company determined that the effective interest rate of this financial liability was 20%.

13. Share Capital (continued)

Preferred shares (continued)

At as November 30, 2020 and August 31, 2021, in light of production data generated from the Company's 2020 harvest and sales transactions occurred subsequent to year end, the Company revised the estimates of the cash flow projection for preferred shares capital repayment and dividend and recorded a loss of \$510,521 using the same effective interest rate of 20%. The amortized cost of preferred shares at year end was estimated based on the following assumptions:

- Estimated annual production capacity ranging from approximately 17,000 to 40,000 kilograms of dry biomass which is highly dependent on weather conditions for growing;
- Estimated distillate yield of approximately of 8-13%;
- Lead time of approximately 4-5 months to process the biomass to distillate oil;
- The Company has been building inventory and subsequent to year end has commenced in sales. The estimated sales price of distillate oil is between \$4,000 and \$7,000 per kilogram; and
- Payment on delivery.

The following is a continuity schedule for preferred shares as at August 31, 2021:

	\$
Balance, November 30, 2019	-
Preferred shares	2,000,000
Deferred transaction costs	(315,302)
Accretion expenses	39,305
Change in estimate of preferred shares	1,896,095
Balance, November 30, 2020	3,620,098
Change in estimated fair value	510,520
Balance, August 31, 2021	4,130,618
Current portion	1,110,784
Long term portion	3,019,834

Share issuances during the nine months ended August 31, 2021

During the nine months ending August 31, 2021, the Company issued 4,476,000 common shares pursuant to warrants exercised at prices ranging from \$0.20 to \$0.40 for gross proceeds of \$1,230,303. The Company transferred \$60,103 from reserve to share capital.

During the nine months ended August 31, 2021, the Company issued 1,839,500 common shares pursuant to stock option exercise at prices ranging from \$0.09 to \$0.25 for gross proceeds of \$637,238. The Company transferred \$350,433 from reserve to share capital.

During the nine months ended August 31, 2021, Convertible debentures were converted to shares and 5,936,000 shares were issued with a fair value of \$1,242,948, extinguishing \$1,103,917 in principal debt, accretion and related interest.

On June 8, 2021, the Company closed an oversubscribed non-brokered private placement and issued 6,283,813 Units of the Company for gross proceeds of \$2,639,201. Each Unit consist of one common share and one-half warrant (with two half warrants being a "Warrant"). Each Warrant entitles the holder to purchase one additional common share at a price of \$0.65 per share for period of 30 months from the date of issuance. The Company paid cash finder's fees of \$34,020 and issued 81,000 Broker Warrants and 230,546 Broker Units. The Broker Warrants and Broker Units carry the same terms noted above. The Broker Warrants fair value was \$50,389. The fair value of the options was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price - \$0.65; exercise price - \$0.65; expected life - 2 year; volatility - 100%; dividend yield - \$0; and risk-free rate - 0.75%.

13. Share Capital (continued)

Share issuances during the nine months ended August 31, 2021 (continued)

On December 9, 2020 the Company closed a non-brokered private placement of 5,540,000 units of the Company at a price of \$0.30 per unit for gross proceeds of \$1,662,000. Each unit consists of one common share and one half of one transferable share purchase warrant, with each whole warrant exercisable into a common share. Each warrant entitles the holder thereof to purchase one additional share at a price of \$0.50 per share for a period of two years from the date of issuance.

The Company issued 300,000 common shares with a fair value of \$60,000, pursuant to a soil purchase agreement.

Share issuances during the nine-month period ended August 31, 2020

On August 20, 2020 the Company closed a non-brokered private placement of 2,000,000 Class B preferred shares at a price of \$1.00 per preferred share for gross proceeds of \$2,000,000. The Company recorded an obligation to issue common shares for 1,000,000 common shares with a fair value of \$300,000 (Note 11).

On July 28, 2020 the Company closed a non-brokered private placement of 470,881 common shares for gross proceeds of \$141,264.

On July 14, 2020 the Company closed a non-brokered private placement of 5,013,222 common shares for gross proceeds of \$1,503,967. No finder's fee was paid on the private placement.

During the period ended August 31, 2020, 1,806,600 options were exercised at \$0.09 per share for proceeds of \$162,594. Pursuant to these exercised options, the Company transferred \$160,007 from reserve to share capital.

The Company entered into a departure agreement with the former CEO. Pursuant to the terms of the agreement, the Company issued 604,110 compensation shares on January 27, 2020 with a fair value of \$120,822. The Company recorded an obligation to issue shares of \$104,932 upon entering the agreement. The obligation was removed and the share capital was increased accordingly, with an additional \$15,890 recognized as share-based compensation during the three months ended February 29, 2020.

Escrow Shares

As at November 30, 2020, a total of 23,932,239 securities, including 19,977,852 shares (November 30, 2019 – 5,000,000), 3,477,387 warrants (November 30, 2019 – Nil), 477,000 stock options (November 30, 2019 – Nil) and 43 convertible debentures (November 30, 2019 – Nil), are held in escrow and will be released based on the following:

On October 1, 2020, the date on which the Company was listed on Canadian Securities Exchange ("Listing Date"), 2,219,762 common shares were released from escrow. The remaining 19,977,852 common shares will be released pursuant to the following schedule:

On the Listing date	1/10 of the escrow securities
6 months after the Listing Date	1/6 of the remaining escrow securities
12 months after the Listing Date	1/5 of the remaining escrow securities
18 months after the Listing Date	1/4 of the remaining escrow securities
24 months after the Listing Date	1/3 of the remaining escrow securities
30 months after the Listing Date	1/2 of the remaining escrow securities
36 months after the Listing Date	the remaining escrow securities

13. Share Capital (continued)

Warrants

The continuity of the Company's share purchase warrants pursuant is as follows:

	Number of share purchase warrants #	Weighted average exercise price \$
Outstanding, November, 30, 2019	17,633,549	0.29
Granted	771,000	0.20
Exercised	(3,606,800)	0.20
Expired	(1,211,250)	0.20
Outstanding, November, 30, 2020	13,586,499	0.32
Granted	6,108,178	0.58
Exercised	(4,476,000)	0.26
Expired	(224,000)	0.20
Outstanding, August 31, 2021	14,994,677	0.44

As of August 31, 2021, the Company had share purchase warrants outstanding and exercisable to acquire common shares of the Company as follows:

Expiry date	Exercise price \$	Number of warrants, issued and exercisable #
October 22, 2022	0.09	1,460,000
December 31, 2021	0.40	7,426,499
December 9, 2022	0.50	2,770,002
December 8, 2023	0.65	3,338,176
		14,994,677

On February 21, 2020, the Company extended the expiry dates of 2,293,799 warrants expiring on October 17, 2020 to December 31, 2021.

On April 14, 2020, the Company extended the expiry dates of 6,062,500 warrants expiring on September 30, 2020 to December 31, 2021.

On September 14, 2020, the Company extended the expiry dates of 442,200 warrants expiring on September 20, 2020 and 100,800 warrants expiring on October 17, 2020 to December 31, 2021.

Stock Options

On March 1, 2017, the Board of Directors approved the adoption of a fixed Stock Option Plan reserving for issuance, upon the exercise of options granted pursuant to the Stock Option Plan, a maximum of 20% of the issued and outstanding shares of the Company, less any shares required to be reserved with respect to options granted by the Company prior to the implementation of the Stock Option Plan. The Stock Option Plan was subsequently replaced with the 2018 Plan which was approved by shareholders at its January 9, 2019 Annual General and Special Meeting. The 2018 Plan is substantively similar to the Stock Option Plan except that it increases the number of common shares reserved under it. The 2018 Plan reserves 8,158,321 common shares (which represents 20% of the Company's outstanding common shares as of the record date for the Meeting), compared to 199,520 under the Stock Option Plan.

13. Share Capital (continued)

Stock Options (continued)

On December 13, 2019, the Company issued 1,540,000 Options to certain employees, with a fair value of \$257,869, to acquire one additional common share at a price of \$0.09 until December 13, 2024. The fair value of the options was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price - \$0.20; exercise price - \$0.09; expected life – 5 year; volatility – 100%; dividend yield – \$0; and risk-free rate – 1.59%. These stock options vest 33% on issue, 33% on the first anniversary and 34% on the second anniversary. For the year ended November 30, 2020, an amount of \$185,943 was recorded as stock-based compensation with a corresponding credit to reserves as a result of the graded vesting terms. For the period ended February 28, 2021, the Company recorded share-based compensation of \$24,851.

On August 20, 2020, the Company issued 6,875,000 Options to certain directors, officers and consultants of the Company to acquire one additional common share at price between \$0.09 and \$0.25 per common share for terms of between six months and five years. The fair value of the options was determined using the Black Scholes Option Pricing Model with the following assumptions summarized in below table. \$1,117,284 stock-based compensation was recorded as a result of various vesting terms for the year ended November 30, 2020. During the period ended August 31, 2020, the Company recorded share-based compensation of \$278,617.

On September 8, 2020, the Company issued 450,000 Options to certain consultants of the Company to acquire one additional common share at price of \$0.25 per common share for three to four years. The fair value of the options was determined using the Black Scholes Option Pricing Model with weighted average assumptions summarized in below table. \$47,812 stock-based compensation was recorded as a result of various vesting terms for the year ended November 30, 2020. During the period ended August 31, 2021, the Company recorded share-based compensation of \$22,176.

On January 8, 2021, the Company issued 200,000 stock options with an exercise price of \$0.88 and expires five years from the date of grant. The fair value of the options was determined using the Black Scholes Option Pricing Model totalling \$28,942.

On May 4, 2021, the Company issued 175,000 stock options with an exercise price of \$0.61 and expires five years from the date of grant. The fair value of the options was determined using the Black Scholes Option Pricing Model totalling \$7,818.

with the following weighted average assumptions:

	Nine months period ended August 31, 2021	Year ending November 30, 2020
Exercise price	\$0.63 to \$0.88	\$0.09 to \$0.40
Expected life	5 years	6 months to 5 years
Volatility	80% to 100%	100%
Risk-free-rate	0.34%	0.30% to 1.59%

13. Share Capital (continued)

Stock Options (continued)

The continuity of the Company's share purchase options is as follows:

	Number of share purchase options #	Weighted average exercise price \$
Outstanding, November 30, 2019	5,080,000	0.09
Granted	11,215,000	0.17
Exercised	(2,356,100)	0.11
Cancelled	(300,000)	(0.09)
Outstanding, November 30, 2020	13,638,900	0.15
Granted	375,000	0.75
Exercised	(1,839,500)	0.16
Cancelled	(50,000)	(0.25)
Outstanding, August 31, 2021	12,124,400	0.17

The weighted average price of shares at the time the options were exercised was \$0.17.

As of August 31, 2021, the Company had share purchase options outstanding and exercisable to acquire common shares of the Company as follows:

Expiry date	Exercise price \$	Number of options issued #	Number of options exercisable #
June 1, 2024	0.09	2,470,000	2,470,000
August 14, 2022	0.20	10,000	10,000
December 13, 2024	0.09	1,269,400	755,999
August 20, 2024	0.09	2,500,000	2,500,000
August 20, 2024	0.25	400,000	400,000
August 20, 2025	0.20	225,000	50,000
August 20, 2025	0.25	275,000	212,500
August 20, 2025	0.15	2,050,000	1,125,000
August 20, 2025	0.09	300,000	150,000
September 8, 2024	0.25	300,000	112,500
September 29, 2025	0.20	850,000	850,000
November 26, 2025	0.40	1,100,000	1,100,000
January 8, 2026	0.88	200,000	50,000
May 4, 2026	0.61	175,000	-
		12,124,400	9,785,999

Reserve

The reserve account records items recognized as stock-based compensation expense and the fair value of finders' warrants issued until such time that the stock options and warrants are exercised, at which time the corresponding amount will be reallocated to share capital.

13. Share Capital (continued)

Obligation to issue shares

During the month period ending August 31, 2021, the Company has an obligation to issue 250,000 shares (November 30, 2020 - 250,000 shares) to the CEO in lieu of cash for consulting fees in the amount of \$190,000 (November 30, 2020 - \$89,500).

During the year ended November 30, 2020, the Company recorded an obligation to issue shares of \$679,500. The Company received \$530,000 in cash for a private placement that was completed on December 9, 2020.

14. Financial instruments

The Company classifies its financial instruments into categories as follows: cash and subscriptions receivable as financial assets at amortized cost, and accounts payable, preferred shares, convertible debenture and government loan as other financial liabilities at amortized cost.

Fair value

Cash is carried at fair market value based on quoted market prices in an active market. The carrying value of accounts payable approximate its fair values due to the short-term nature of these financial instruments. Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 – unadjusted quoted prices in active markets for identical assets and liabilities;
- Level 2 – inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – inputs that are not based on observable market data.

Cash is measured using level 1 inputs. Preferred shares are measured using level 3 inputs.

14. Financial risk and capital management

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash held in bank accounts and subscription receivable. The majority of cash is deposited in bank accounts held with a major bank in Canada. As most of the Company's cash is held by one bank there is a concentration of credit risk. This risk is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. Credit risk related to cash is assessed as low.

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to foreign exchange risk.

15. Financial risk and capital management (continued)

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash. As of August 31, 2021, the Company has cash of \$1,427,006 (November 30, 2020 - \$1,844,356) to cover short term obligations.

Historically, the Company's sole source of funding has been loans from related parties, convertible debentures, preferred share financings and private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. Liquidity risk is assessed as high.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As at August 31, 2021, the Company has convertible debentures of \$3,708,157 and government loans of \$40,000, which bears a fixed interest rate and a nil interest rate, respectively. As such, the Company's interest rate risk is low.

Capital Management

The Company's policy is to maintain a strong capital base so as to maintain investor and creditor confidence and to sustain future development of the business. The capital structure of the Company consists of equity and cash. There were no changes in the Company's approach to capital management during the year. The Company is not subject to any externally imposed capital requirements.

16. Subsequent events

On September 30, 2021, the Company granted 1,000,000 restricted share units ("RSUs") to the President of the Company. 250,000 of the RSUs vest immediately upon issuance, with the balance to vest in three increments of 250,000 over 18 months. The RSUs were priced at \$0.37 based on the closing price of the common shares on the Canadian Securities Exchange on September 29, 2021.

Subsequent to the period ended August 31, 2021, the Company issued 150,000 common shares pursuant to an option exercise.